Live Analyst Rating Changes 27424 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Gustavo Miele
GS

Gustavo Miele

Goldman Sachs
Wall Street Analyst
★★★★☆
#392
on 13Foresight · ranked by our own returns
33%
Success Rate
-14.7%
Average Return
5 of 15 calls profitable · +52.5% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 33% of Gustavo Miele's ratings turned a profit when each position was held for 1 year — averaging -14.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

12 Buy 6 Hold 2 Sell
Gustavo's Stock Coverage 15 ratings · 2026-08-25
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
BR:BLAU3
Blau Farmaceutica SA
 Jul 15, 2026 SELL Sell
+22.4% avg upside
2 analysts
$10.00
11.64% Upside
 +7.9% ·
BR:ONCO3
Oncoclinicas do Brasil Servicos Medicos SA
 Jun 26, 2026 HOLD Hold
1 analyst
 — -6.5% ·
BR:SAUD3
OdontoPrev S.A.
 Jun 25, 2026 BUY Strong Buy
+15.0% avg upside
1 analyst
$16.00
15.00% Upside
 -0.0% ·
BR:HAPV3
Hapvida Participacoes e Investimentos SA
 May 27, 2026 HOLD Hold
+91.2% avg upside
2 analysts
$12.50
91.20% Upside
 -47.3% ·
AMX
America Movil
 May 22, 2026 BUY Strong Buy
+0.3% avg upside
17 analysts
$31.80
33.64% Upside
 -7.9% ·
TIMB
TIM
 May 18, 2026 HOLD Hold
+9.6% avg upside
11 analysts
$23.40
31.14% Upside
 -18.9% ·
VIV
Telefonica Brasil
 May 17, 2026 SELL Buy
+2.7% avg upside
12 analysts
$13.90
21.53% Upside
 +15.0% ·
BR:ANIM3
Anima Holding SA
 Feb 10, 2026 BUY Strong Buy
+132.1% avg upside
2 analysts
$5.50
132.12% Upside
 -46.7% ·
BR:COGN3
Cogna Educacao S.A.
 Jan 28, 2026 BUY Strong Buy
+108.5% avg upside
3 analysts
$5.00
136.91% Upside
 -53.1% ·
BR:FLRY3
Fleury SA
 Jan 20, 2026 BUY Strong Buy
-3.7% avg upside
1 analyst
$18.00
3.74% Downside
 +22.1% ·
BR:YDUQ3
YDUQS Participacoes SA
 Dec 02, 2025 HOLD Hold
1 analyst
 — -39.5% ·
BR:MATD3
Hospital Mater Dei SA
 Nov 13, 2025 BUY Strong Buy
+41.6% avg upside
1 analyst
$7.00
41.63% Upside
 +8.4% ·
BR:RDOR3
Rede D'Or Sao Luiz SA
 Nov 11, 2025 BUY Strong Buy
+29.1% avg upside
2 analysts
$52.00
51.91% Upside
 -17.9% ·
BR:QUAL3
Qualicorp Consultoria e Corretora de Seguros S.A.
 Oct 27, 2025 HOLD Hold
+55.3% avg upside
1 analyst
$2.50
55.30% Upside
 -40.2% ·
AFYA
Afya
 Dec 03, 2024 SELL Sell
+17.0% avg upside
8 analysts
$16.00
11.71% Upside
 +3.6% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Gustavo Miele — Frequently Asked Questions
How accurate are Gustavo Miele's stock ratings?
Based on the calls 13Foresight could measure, about 33% of Gustavo's ratings were profitable over a one-year hold, with an average return of -14.7% per rating, or +52.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Gustavo ranked on 13Foresight?
Gustavo Miele is currently ranked #392 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Gustavo cover?
Gustavo most recently has ratings on BR:BLAU3, BR:ONCO3, BR:SAUD3, BR:HAPV3, AMX, TIMB, VIV, BR:ANIM3, BR:COGN3, BR:FLRY3, BR:YDUQ3, BR:MATD3 and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.